vs
Side-by-side financial comparison of ORASURE TECHNOLOGIES INC (OSUR) and Valens Semiconductor Ltd. (VLN). Click either name above to swap in a different company.
ORASURE TECHNOLOGIES INC is the larger business by last-quarter revenue ($26.8M vs $17.3M, roughly 1.5× Valens Semiconductor Ltd.). Valens Semiconductor Ltd. runs the higher net margin — -42.2% vs -72.1%, a 29.8% gap on every dollar of revenue. On growth, Valens Semiconductor Ltd. posted the faster year-over-year revenue change (8.1% vs -28.5%). Valens Semiconductor Ltd. produced more free cash flow last quarter ($-4.9M vs $-9.9M).
OraSure Technologies, Inc. is a Bethlehem, Pennsylvania–based company in the medical device industry. Their products include diagnostic testing kits. The company had recently developed OraQuick testing kit, the first over-the-counter home HIV test.
Valens Semiconductor (Valens) is an Israeli fabless manufacturing company providing semiconductors for the automotive and audio-video industries. Valens provides semiconductor products for the distribution of uncompressed ultra-high-definition (UHD) multimedia content and in-vehicle connectivity applications. The company is a member of the MIPI Alliance and developed the first-to-market chipset that is compliant with the MIPI A-PHY standard. Valens invented the technology behind the HDBaseT s...
OSUR vs VLN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | ||
|---|---|---|
| Revenue | $26.8M | $17.3M |
| Net Profit | $-19.3M | $-7.3M |
| Gross Margin | 41.0% | 63.0% |
| Operating Margin | -75.1% | -46.4% |
| Net Margin | -72.1% | -42.2% |
| Revenue YoY | -28.5% | 8.1% |
| Net Profit YoY | -78.7% | 29.3% |
| EPS (diluted) | $-0.28 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.8M | — | ||
| Q3 25 | $27.1M | $17.3M | ||
| Q2 25 | $31.2M | $17.1M | ||
| Q1 25 | $29.9M | $16.8M | ||
| Q4 24 | $37.4M | — | ||
| Q3 24 | $39.9M | $16.0M | ||
| Q2 24 | $54.3M | $13.6M | ||
| Q1 24 | $54.1M | — |
| Q4 25 | $-19.3M | — | ||
| Q3 25 | $-13.7M | $-7.3M | ||
| Q2 25 | $-19.7M | $-7.2M | ||
| Q1 25 | $-16.0M | $-8.3M | ||
| Q4 24 | $-10.8M | — | ||
| Q3 24 | $-4.5M | $-10.4M | ||
| Q2 24 | $-615.0K | $-8.9M | ||
| Q1 24 | $-3.6M | — |
| Q4 25 | 41.0% | — | ||
| Q3 25 | 43.5% | 63.0% | ||
| Q2 25 | 42.1% | 63.5% | ||
| Q1 25 | 41.1% | 62.9% | ||
| Q4 24 | 36.2% | — | ||
| Q3 24 | 42.8% | 56.4% | ||
| Q2 24 | 45.4% | 61.4% | ||
| Q1 24 | 44.5% | — |
| Q4 25 | -75.1% | — | ||
| Q3 25 | -59.4% | -46.4% | ||
| Q2 25 | -57.7% | -43.3% | ||
| Q1 25 | -59.3% | -56.2% | ||
| Q4 24 | -33.2% | — | ||
| Q3 24 | -15.0% | -76.3% | ||
| Q2 24 | -5.0% | -69.2% | ||
| Q1 24 | -13.1% | — |
| Q4 25 | -72.1% | — | ||
| Q3 25 | -50.6% | -42.2% | ||
| Q2 25 | -63.0% | -42.1% | ||
| Q1 25 | -53.6% | -49.4% | ||
| Q4 24 | -28.8% | — | ||
| Q3 24 | -11.3% | -64.6% | ||
| Q2 24 | -1.1% | -65.2% | ||
| Q1 24 | -6.6% | — |
| Q4 25 | $-0.28 | — | ||
| Q3 25 | $-0.19 | $-0.07 | ||
| Q2 25 | $-0.26 | $-0.07 | ||
| Q1 25 | $-0.21 | $-0.08 | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.06 | $-0.10 | ||
| Q2 24 | $-0.01 | $-0.08 | ||
| Q1 24 | $-0.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $199.3M | $93.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $340.8M | $108.8M |
| Total Assets | $403.2M | $136.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $199.3M | — | ||
| Q3 25 | $216.5M | $93.5M | ||
| Q2 25 | $234.6M | $102.7M | ||
| Q1 25 | $247.6M | $112.5M | ||
| Q4 24 | $267.8M | — | ||
| Q3 24 | $278.6M | $133.1M | ||
| Q2 24 | $267.4M | $105.9M | ||
| Q1 24 | $263.8M | — |
| Q4 25 | $340.8M | — | ||
| Q3 25 | $362.0M | $108.8M | ||
| Q2 25 | $380.7M | $116.5M | ||
| Q1 25 | $396.3M | $128.6M | ||
| Q4 24 | $410.3M | — | ||
| Q3 24 | $425.6M | $147.0M | ||
| Q2 24 | $425.8M | $153.5M | ||
| Q1 24 | $426.3M | — |
| Q4 25 | $403.2M | — | ||
| Q3 25 | $423.1M | $136.7M | ||
| Q2 25 | $445.0M | $144.8M | ||
| Q1 25 | $457.6M | $154.6M | ||
| Q4 24 | $479.7M | — | ||
| Q3 24 | $464.1M | $171.9M | ||
| Q2 24 | $466.3M | $175.8M | ||
| Q1 24 | $467.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $-9.0M | $-4.7M |
| Free Cash FlowOCF − Capex | $-9.9M | $-4.9M |
| FCF MarginFCF / Revenue | -37.1% | -28.5% |
| Capex IntensityCapex / Revenue | 3.4% | 1.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-53.2M | $-11.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.0M | — | ||
| Q3 25 | $-10.1M | $-4.7M | ||
| Q2 25 | $-10.2M | $-211.0K | ||
| Q1 25 | $-19.7M | $-7.6M | ||
| Q4 24 | $109.0K | — | ||
| Q3 24 | $12.7M | $3.0M | ||
| Q2 24 | $7.8M | $-225.0K | ||
| Q1 24 | $6.7M | — |
| Q4 25 | $-9.9M | — | ||
| Q3 25 | $-11.0M | $-4.9M | ||
| Q2 25 | $-12.2M | $-330.0K | ||
| Q1 25 | $-20.2M | $-8.0M | ||
| Q4 24 | $-347.0K | — | ||
| Q3 24 | $12.5M | $2.2M | ||
| Q2 24 | $6.2M | $-460.0K | ||
| Q1 24 | $5.2M | — |
| Q4 25 | -37.1% | — | ||
| Q3 25 | -40.6% | -28.5% | ||
| Q2 25 | -38.9% | -1.9% | ||
| Q1 25 | -67.3% | -47.3% | ||
| Q4 24 | -0.9% | — | ||
| Q3 24 | 31.4% | 14.0% | ||
| Q2 24 | 11.5% | -3.4% | ||
| Q1 24 | 9.5% | — |
| Q4 25 | 3.4% | — | ||
| Q3 25 | 3.4% | 1.6% | ||
| Q2 25 | 6.2% | 0.7% | ||
| Q1 25 | 1.4% | 2.1% | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 0.4% | 4.5% | ||
| Q2 24 | 3.0% | 1.7% | ||
| Q1 24 | 2.9% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OSUR
| Product And Services | $24.9M | 93% |
| Other | $1.9M | 7% |
VLN
Segment breakdown not available.